Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Evenity Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentCignaPolicy IP0179

    Bone Modifiers - Evenity

    Customize your policy alerts

    Sign up for Cigna Policy IP0179 alerts

    Get alerted when Policy IP0179 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-benefit coverage of Evenity for postmenopausal patients with osteoporosis. Coverage requires specified clinical severity, prior-treatment or exception criteria, dosing limits, and covered HCPCS coding.

    Policy Summary
    PayerCigna
    PolicyBone Modifiers - Evenity
    Policy CodePolicy IP0179
    Change TypeMaterial update
    Effective DateNovember 15, 2026
    Last ReviewDec 4, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization for medical-benefit coverage of Evenity and document the applicable indication and dosing requirements.
    SourceLink
    POLICY UPDATE CHANGES

    An exception was added allowing the bisphosphonate-trial requirement to be bypassed for patients with a very low T-score below -3.0.

    Approval criteria were added for patients who cannot take an oral bisphosphonate and for patients with severe renal impairment or chronic kidney disease.

    HCPCS code J3111 was added for billing Evenity.

    The policy clarifies that calcium and vitamin D supplements may be used with Evenity while concurrent osteoporosis medications are not covered.

    12Maximum doses per therapy course
    210 mg monthlyDosing schedule
    1 year

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Approval duration
    J3111Covered billing code
    < -3.0Very low T-score exception

    Covered and Noncovered Uses

    FDA-approved indication: osteoporosis treatment in a postmenopausal patient

    Covered and approved for 1 year when ALL of the following are met.

    All approval requirements

    • Osteoporosis severity or fracture-risk pathway

      • T-score criterion: The patient has a current or historical T-score at or below -2.5 at the lumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist).≤ -2.5
      • Fracture criterion: The patient has had an osteoporotic fracture or a fragility fracture.
      • Low bone mass and high fracture risk

        • The patient has low bone mass, defined as a current or historical T-score between -1.0 and -2.5 at the lumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist).Between -1.0 and -2.5
        • According to the prescriber, the patient is at high risk for fracture.
    • Prior therapy or clinical-exception pathway

      • Prior intravenous bisphosphonate: The patient has tried intravenous ibandronate or intravenous zoledronic acid (Reclast).
      • Oral bisphosphonate trial

        • The patient has tried at least one oral bisphosphonate or oral bisphosphonate-containing product and experienced inadequate efficacy after a trial duration of 12 months.12 months
        • The patient has tried at least one oral bisphosphonate or oral bisphosphonate-containing product and experienced significant intolerance.
      • Unable to take an oral bisphosphonate

        • The patient cannot swallow or has difficulty swallowing.
    • Therapy-course limit: The patient has received no more than 12 monthly doses during this therapy course.≤ 12 monthly doses

    Osteoporosis prevention is not covered because Evenity is not indicated for the prevention of osteoporosis.

    Concurrent use with other osteoporosis medications is not covered. This includes oral or intravenous bisphosphonates, denosumab products, teriparatide products, Tymlos, and calcitonin nasal spray. Calcium and/or vitamin D supplements may be used with Evenity.

    Evenity should not be initiated in a patient who had a myocardial infarction or stroke within the preceding year. If myocardial infarction or stroke occurs during therapy, Evenity should be discontinued.

    Use of Evenity for osteoporosis prevention is considered not medically necessary.

    Concurrent use of Evenity with other osteoporosis medications is considered not medically necessary.

    Any other use that does not meet the listed coverage criteria is considered not medically necessary.

    Covered Coding and Clinical Thresholds

    Considered Medically Necessary HCPCS CodeHCPCSCovered
    J3111Injection, romosozumab-aqqg, 1 mg
    Osteoporosis T-score
    ThresholdT-score at or below -2.5
    Measurement sitesLumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist)
    TimingCurrent or at any time in the past
    Low bone mass T-score range
    T-score rangeBetween -1.0 and -2.5
    Measurement sitesLumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist)
    Timing

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for medical-benefit coverage of Evenity. Approval is recommended only when the patient meets the policy criteria and dosing requirements; approvals are issued for the applicable duration.

    Documentation Required

    Document Bisphosphonate History or Exception

    Document the patient's relevant bisphosphonate history or the clinical exception supporting Evenity. The record must identify prior intravenous or oral bisphosphonate treatment, or explain why an oral bisphosphonate cannot be used.

    • Prior intravenous therapy: ibandronate or zoledronic acid (Reclast).
    • Prior oral bisphosphonate therapy may qualify after inadequate efficacy following a 12-month trial or significant intolerance.
    • An exception may apply when the patient cannot swallow, cannot remain upright after administration, or has a pre-existing gastrointestinal condition; severe renal impairment, an osteoporotic or fragility fracture, or a very low T-score may also qualify under the policy.

    Therapy Overview

    Evenity (romosozumab-aqqg) is a sclerostin inhibitor used to treat osteoporosis in postmenopausal patients at high or very high fracture risk. Its anabolic effect wanes after 12 monthly doses; antiresorptive therapy should then be considered to maintain bone-density gains and reduce fracture risk. Calcium and vitamin D supplementation is recommended during treatment.

    Clinical Definitions

    Low bone mass
    DefinitionBone mass with a T-score between -1.0 and -2.5
    Measurement sitesLumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist)
    TimingT-score may be current or historical
    Severe renal impairment
    Policy exampleCreatinine clearance below 35 mL/minute
    ConditionSevere renal impairment or chronic kidney disease
    Coverage roleQualifying exception to the prior-treatment pathway

    Initial Approval Criteria

    Postmenopausal osteoporosis approval

    Approve for 1 year when ALL of the following are met.

    Initial approval requirements

    • Postmenopausal osteoporosis severity or fracture-risk requirement

      • The patient has a current or historical T-score at or below -2.5 at the lumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist).≤ -2.5
      • The patient has had an osteoporotic fracture or a fragility fracture.
      • Low bone mass and high fracture risk

        • The patient has low bone mass, with a current or historical T-score between -1.0 and -2.5 at the lumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist).

    Continuation and Additional Doses

    Maximum 12-dose course

    Continuation or additional doses are covered only within the established therapy-course limit.

    Continuation dose limit

    • Established dosing schedule: The patient receives 210 mg of Evenity subcutaneously once every month.210 mg subcutaneously once every month
    • Maximum course duration: The patient has received no more than 12 monthly doses during the therapy course.≤ 12 monthly doses

      The anabolic effect wanes after 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an antiresorptive therapy such as alendronate should be considered.

    Required Prior Bisphosphonate Therapy

    StepRequirementQualifying pathway or exception
    1The patient must have tried an intravenous bisphosphonate or an oral bisphosphonate or bisphosphonate-containing product, unless an allowed exception applies.Prior intravenous ibandronate or intravenous zoledronic acid (Reclast).
    1The patient must have tried an intravenous bisphosphonate or an oral bisphosphonate or bisphosphonate-containing product, unless an allowed exception applies.Oral bisphosphonate trial with inadequate efficacy after 12 months or significant intolerance, including severe gastrointestinal-related or musculoskeletal-related adverse events.
    1The patient must have tried an intravenous bisphosphonate or an oral bisphosphonate or bisphosphonate-containing product, unless an allowed exception applies.Unable to take an oral bisphosphonate because of difficulty swallowing, inability to remain upright after administration, or a pre-existing gastrointestinal condition.
    1The patient must have tried an intravenous bisphosphonate or an oral bisphosphonate or bisphosphonate-containing product, unless an allowed exception applies.Severe renal impairment or chronic kidney disease; an example is creatinine clearance below 35 mL/minute.
    1The patient must have tried an intravenous bisphosphonate or an oral bisphosphonate or bisphosphonate-containing product, unless an allowed exception applies.Osteoporotic or fragility fracture.
    1The patient must have tried an intravenous bisphosphonate or an oral bisphosphonate or bisphosphonate-containing product, unless an allowed exception applies.Very low T-score below -3.0; this exception allows the bisphosphonate-trial requirement to be bypassed.

    Dose and Course Limits

    Evenity (romosozumab-aqqg)
    Dose210 mg
    RouteSubcutaneous administration
    FrequencyOnce every month
    Maximum quantityNo more than 12 monthly doses during a therapy course
    Policy Summary
    PayerCigna
    PolicyBone Modifiers - Evenity
    Policy CodePolicy IP0179
    Change TypeMaterial update
    Effective DateNovember 15, 2026
    Last ReviewDec 4, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization for medical-benefit coverage of Evenity and document the applicable indication and dosing requirements.
    SourceLink
    On This Page
    Covered and Noncovered UsesCovered Coding and Clinical ThresholdsAuthorization, Documentation, and Denial RisksTherapy OverviewClinical DefinitionsInitial Approval CriteriaContinuation and Additional DosesRequired Prior Bisphosphonate TherapyDose and Course Limits
    The patient cannot remain in an upright position after oral bisphosphonate administration.
  1. The patient has a pre-existing gastrointestinal medical condition, such as an esophageal lesion, esophageal ulcer, stricture, or achalasia.
  2. Other qualifying exception

    • According to the prescriber, the patient has severe renal impairment or chronic kidney disease.Example: creatinine clearance < 35 mL/minute
    • The patient has had an osteoporotic fracture or a fragility fracture.
    • The patient has a very low T-score.< -3.0

      This exception allows the bisphosphonate-trial requirement to be bypassed.

  3. Current or at any time in the past
    Very low T-score
    ThresholdT-score below -3.0
    ExceptionVery low T-score is a qualifying clinical exception
    EffectMay allow the bisphosphonate-trial requirement to be bypassed
    Severe renal impairment example
    Example thresholdCreatinine clearance less than 35 mL/minute
    Related conditionSevere renal impairment or chronic kidney disease
    Policy roleQualifying clinical-exception pathway
    Inadequate oral bisphosphonate efficacy trial
    Required trial duration12 months
    TherapyOral bisphosphonate therapy
    AssessmentInadequate efficacy according to the prescriber
    Maximum Evenity therapy course
    Maximum courseNo more than 12 monthly doses
    FrequencyOne dose every month
    Course basisLimit applies during a therapy course
    Documentation Required

    Document Osteoporosis Severity and Fracture Risk

    Document osteoporosis severity and fracture risk supporting treatment for a postmenopausal patient. The patient must meet at least one qualifying severity or fracture-risk pathway.

    • Current or historical T-score at or below -2.5 at the lumbar spine, femoral neck, total hip, or 33% radius.
    • Osteoporotic or fragility fracture.
    • Low bone mass, such as a T-score between -1.0 and -2.5, together with prescriber-documented high fracture risk.
    • When applicable, document a very low T-score below -3.0.
    Documentation Required

    Document Prior Therapy and Qualifying Exceptions

    Document the prior therapy outcome or the specific qualifying exception used to support the request. Clinical records should connect the patient's history to the applicable policy pathway.

    • For inadequate efficacy, document at least 12 months of oral bisphosphonate therapy and ongoing significant BMD loss, no BMD increase, or an osteoporotic or fragility fracture.
    • For significant intolerance, document severe gastrointestinal or musculoskeletal adverse events.
    • For inability to use oral therapy, document swallowing difficulty, inability to remain upright, or a relevant gastrointestinal condition such as an esophageal lesion, ulcer, stricture, or achalasia.
    • For severe renal impairment or chronic kidney disease, document the condition; an example threshold is creatinine clearance below 35 mL/minute.
    Billing Rule

    Document Dose History and Requested Regimen

    Record the patient's prior Evenity dose history and the requested regimen. The established regimen is limited to 12 monthly doses during a therapy course.

    • Requested dose: 210 mg administered subcutaneously once every month.
    • Document that no more than 12 monthly doses have been received during the therapy course.
    • Requests outside the established dosing may be reviewed case by case by a clinician, such as a Medical Director or Pharmacist.
    Denial Risk

    Failure to Meet Criteria or Dosing Limits

    Coverage may be denied when the patient does not meet the medical-necessity criteria or when the requested regimen exceeds the policy's dosing limits.

    • Approval is limited to patients meeting all required criteria for the FDA-approved postmenopausal osteoporosis indication.
    • More than 12 monthly doses during the therapy course do not meet the stated criteria.
    • Doses outside the established regimen require case-by-case clinical review and are not automatically approved.
    Denial Risk

    Noncovered Uses

    Evenity is not medically necessary for prevention of osteoporosis or for concurrent use with other osteoporosis medications.

    • Do not use for osteoporosis prevention.
    • Do not administer concurrently with oral or intravenous bisphosphonates, denosumab products, teriparatide products, Tymlos (abaloparatide), or calcitonin nasal spray.
    • Calcium and/or vitamin D supplements may be used concurrently.
    Denial Risk

    Cardiovascular Safety Restriction

    Assess cardiovascular risk before and during treatment because Evenity carries a boxed warning for myocardial infarction, stroke, and cardiovascular death.

    • Do not initiate Evenity in a patient who had a myocardial infarction or stroke within the preceding year.
    • Consider whether benefits outweigh risks in patients with other cardiovascular risk factors.
    • Discontinue Evenity if the patient experiences a myocardial infarction or stroke during therapy.
    Billing Rule

    Use Supported Diagnosis and Procedure Coding

    Claims may be denied when the submission is not accompanied by covered diagnosis and/or procedure codes under the applicable policy. Providers must use the most appropriate codes in effect on the submission date.

    • Verify that the diagnosis and procedure codes support the covered indication and service.
    • Services billed for conditions or diagnoses not covered by the policy are not reimbursable.
    • Missing, unsupported, or noncovered coding may result in denial as not covered.
    Inadequate efficacy
    Bone mineral densityOngoing and significant loss of bone mineral density
    Treatment responseNo increase in bone mineral density
    Fracture outcomeOsteoporotic fracture or fragility fracture after treatment
    Significant intolerance
    DefinitionSignificant intolerance to an oral bisphosphonate
    Gastrointestinal examplesSevere gastrointestinal-related adverse events
    Musculoskeletal examplesSevere musculoskeletal-related adverse events
    Between -1.0 and -2.5
  4. According to the prescriber, the patient is at high risk for fracture.
  5. Qualifying prior therapy or clinical exception

    • The patient has tried intravenous ibandronate or intravenous zoledronic acid (Reclast).
    • Oral bisphosphonate trial

      • The patient has tried at least one oral bisphosphonate or oral bisphosphonate-containing product and experienced inadequate efficacy after a trial duration of 12 months.12 months
      • The patient has tried at least one oral bisphosphonate or oral bisphosphonate-containing product and experienced significant intolerance.
    • Unable to take an oral bisphosphonate

      • The patient cannot swallow or has difficulty swallowing.
      • The patient cannot remain upright after oral bisphosphonate administration.
      • The patient has a pre-existing gastrointestinal medical condition.
    • Other qualifying exception

      • According to the prescriber, the patient has severe renal impairment or chronic kidney disease.Example: creatinine clearance < 35 mL/minute
      • The patient has had an osteoporotic fracture or a fragility fracture.
      • The patient has a very low T-score.< -3.0

        This exception allows the bisphosphonate-trial requirement to be bypassed.

  6. Therapy-course limit: The patient has received no more than 12 monthly doses during this therapy course.≤ 12 monthly doses